Prelude Capital Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Prelude Capital Management’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$506K	Sell	25,997 -22,886	-47%	-$415K	0.04%	524
2026 Q1	$911K	Buy	+48,883	New	+$810K	0.07%	331
2025 Q4	–	Sell	-44,779	Closed	-$321K	–	1460
2025 Q3	$321K	Buy	+44,779	New	+$2.33M	0.03%	702
2024 Q2	–	Sell	-4,149	Closed	-$208K	–	1389
2024 Q1	$208K	Sell	4,149 -6,851	-62%	-$372K	0.01%	1088
2023 Q4	$664K	Buy	11,000 +4,600	+72%	+$237K	0.04%	410
2023 Q3	$365K	Buy	+6,400	New	+$353K	0.02%	583
2022 Q1	–	Sell	-50,000	Closed	-$495K	–	2073
2021 Q4	$495K	Hold	50,000	–	–	0.01%	1020
2021 Q3	$498K	Hold	50,000	–	–	0.01%	896
2021 Q2	$518K	Buy	+50,000	New	+$508K	0.02%	923

Other funds holding MLTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Jupiter Topco New York $245B AUM

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Prelude Capital Management's MLTX Position: Q2 2026 in Review

Prelude Capital Management reduced its MoonLake Immunotherapeutics (MLTX) stake by 47% in Q2 2026, selling an estimated $415K and leaving 25,997 shares worth $506K. The position accounts for 0.04% of the portfolio, ranked #524.

Prelude Capital Management first reported a position in MLTX in Q2 2021 and has held it in 9 quarters since. The position peaked at $911K in Q1 2026. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

Prelude Capital Management held 25,997 shares of MoonLake Immunotherapeutics worth $506K as of Q2 2026.
Prelude Capital Management sold 22,886 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $415K.
MoonLake Immunotherapeutics made up 0.04% of Prelude Capital Management's portfolio in Q2 2026, its #524 holding.
Prelude Capital Management first reported a position in MoonLake Immunotherapeutics in Q2 2021 and has held it in 9 quarters since.
Prelude Capital Management's MoonLake Immunotherapeutics position peaked at $911K in Q1 2026.
173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.